• Markets
  • icon
  • Companies
IMC · ASX

Immuron Limited (ASX:IMC)

AU$0.093

 0.003 (3.333%)
ASX:Live
22/05/2024 02:56:03 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

IMC Overview

IMC Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IMC

Website

N/A

Telephone

Address

Description

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

IMC Price Chart

Key Stats

Market Cap

AU$20.52M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.06 - 0.17

Trade Value (12mth)

AU$12,651.00

1 week

2.2%

1 month

-7%

YTD

20.78%

1 year

17.72%

All time high

15.597999572753906

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

-329.80%

Operating Cashflow

-$2m

Free Cash Flow Return

-11.50%

ROIC

-17.60%

Interest Coverage

-616.60

Quick Ratio

8.80

Other Data

Shares on Issue (Fully Dilluted)

228m

HALO Sector

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

IMC Announcements

Latest Announcements

Date Announcements

03 May 24

Board Change

×

Board Change

03 May 24

Final Director's Interest Notice (SA)

×

Final Director's Interest Notice (SA)

30 April 24

Change in substantial holding

×

Change in substantial holding

23 April 24

Immuron CEO Steven Lydeamore to present at The Watchlist

×

Immuron CEO Steven Lydeamore to present at The Watchlist

15 April 24

Immuron to host Live Virtual Event

×

Immuron to host Live Virtual Event

10 April 24

Immuron Travelan sales continued strong growth

×

Immuron Travelan sales continued strong growth

22 March 24

Change in substantial holding

×

Change in substantial holding

14 March 24

Change in substantial holding

×

Change in substantial holding

14 March 24

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

×

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

14 March 24

Application for quotation of securities - IMC

×

Application for quotation of securities - IMC

14 March 24

Change of Director's Interest Notice (DP)

×

Change of Director's Interest Notice (DP)

14 March 24

Notice under section 708A

×

Notice under section 708A

07 March 24

Travelan to progress to Phase 3 Clinical Trials in the US

×

Travelan to progress to Phase 3 Clinical Trials in the US

05 March 24

Trading Halt

×

Trading Halt

01 March 24

Change in substantial holding

×

Change in substantial holding

28 February 24

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

21 February 24

Presentation to Australian Biologics Festival 2024

×

Presentation to Australian Biologics Festival 2024

13 February 24

Immuron achieves record Travelan sales

×

Immuron achieves record Travelan sales

08 February 24

Investor Webinar Presentation

×

Investor Webinar Presentation

16 January 24

Immuron achieves record half yearly Travelan sales

×

Immuron achieves record half yearly Travelan sales

22 December 23

Immuron Clinical Trials Update

×

Immuron Clinical Trials Update

04 December 23

First Patients Enrolled in Campylobacter Clinical Study

×

First Patients Enrolled in Campylobacter Clinical Study

28 November 23

Investor Webinar Presentation

×

Investor Webinar Presentation

24 November 23

Notification regarding unquoted securities - IMC

×

Notification regarding unquoted securities - IMC

24 November 23

Change of Director's Interest Notice (PB)

×

Change of Director's Interest Notice (PB)

IMC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.01 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -128.3 67.0 -32.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.5 49.1 -35.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.6 -17.5 -14.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.11 0.10 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.11 0.10 0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 259.9 -10.7 -15.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 221 228 228 Lock Lock Lock
Basic m Lock Lock Lock Lock 221 228 228 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 1 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -94.2 424.9 135.8 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 8 5 8 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -94.8 452.8 150.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 65.0 68.4 72.5 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 35 32 27 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -4 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -150.1 51.8 -47.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,742.2 -527.0 -329.8 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -4 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -148.2 51.8 -47.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,772.2 -530.5 -332.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -3 -4 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -186.4 66.0 -32.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,751.6 -373.0 -209.8 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -3 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -3 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 26 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -3 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -29.2 23.2 20.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -28.1 -4.1 -1.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 25 22 19 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 27 25 22 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -25 -22 -19 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 26 23 20 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 26 23 20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 357.3 -9.8 -15.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -31.0 -11.5 -17.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -32.4 -12.3 -19.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -53.2 -16.5 -27.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -53.1 -11.6 -17.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -25.9 -12.7 -11.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -608.3 -652.1 -616.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.0 5.4 3.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -96.6 -94.5 -95.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 23.0 15.8 9.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 22.7 15.5 8.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.3 93.4 93.1 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -364.0 -208.4 -112.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.4 1.5 3.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.1 0.8 0.8 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 73.3 94.2 43.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -6,047.3 -406.7 -213.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -32.6 -12.5 -17.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -31.0 -11.5 -17.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -32.4 -12.3 -19.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -32.4 -12.3 -19.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 3,895.9 467.5 429.6 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 829.3 237.9 109.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 4,725.1 705.4 538.9 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A 547.9 273.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 4,725.1 157.5 265.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMC Shortsell

Frequently Asked Questions

The current share price of Immuron Limited (IMC:ASX) is AU$0.093.
The 52-week high share price for Immuron Limited (IMC:ASX) is AU$0.17.
The 52-week low share price for Immuron Limited (IMC:ASX)? is AU$0.06.
Immuron Limited (IMC:ASX) does not pay a dividend.
Immuron Limited (IMC:ASX) does not pay a dividend.
Immuron Limited (IMC:ASX) has a franking level of 0.0%.
Immuron Limited (IMC:ASX) is classified in the Healthcare.
The current P/E ratio for Immuron Limited (IMC:ASX) is .